520 related articles for article (PubMed ID: 28603071)
61. Allogeneic Hematopoietic Cell Transplantation in Multiple Myeloma: Impact of Disease Risk and Post Allograft Minimal Residual Disease on Survival.
Dhakal B; D'Souza A; Martens M; Kapke J; Harrington AM; Pasquini M; Saber W; Drobyski WR; Zhang MJ; Hamadani M; Hari PN
Clin Lymphoma Myeloma Leuk; 2016 Jul; 16(7):379-86. PubMed ID: 27160644
[TBL] [Abstract][Full Text] [Related]
62. Stem cell mobilization and autologous stem cell transplantation after pretreatment with bendamustine, prednisone and bortezomib (BPV) in newly diagnosed multiple myeloma.
Poenisch W; Plötze M; Holzvogt B; Andrea M; Schliwa T; Zehrfeld T; Hammerschmidt D; Schwarz M; Edelmann T; Becker C; Hoffmann FA; Schwarzer A; Kreibich U; Gutsche K; Reifenrath K; Schwarzbach H; Heyn S; Franke GN; Jentzsch M; Leiblein S; Schwind S; Lange T; Vucinic V; AlAli HK; Niederwieser D
J Cancer Res Clin Oncol; 2015 Nov; 141(11):2013-22. PubMed ID: 25976868
[TBL] [Abstract][Full Text] [Related]
63. Risk Factors for Catheter-Related Thrombosis in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation.
Hoppe A; Rupa-Matysek J; Małecki B; Dytfeld D; Hoppe K; Gil L
Medicina (Kaunas); 2021 Sep; 57(10):. PubMed ID: 34684057
[No Abstract] [Full Text] [Related]
64. The choice of multiple myeloma induction therapy affects the frequency and severity of oral mucositis after melphalan-based autologous stem cell transplantation.
Fleming S; Harrison SJ; Blombery P; Joyce T; Stokes K; Seymour JF; Prince HM; Ritchie D
Clin Lymphoma Myeloma Leuk; 2014 Aug; 14(4):291-6. PubMed ID: 24629850
[TBL] [Abstract][Full Text] [Related]
65. Combined submyeloablative and myeloablative dose intense melphalan results in satisfactory responses with acceptable toxicity in patients with multiple myeloma.
Novitzky N; Thomson J; Thomas V; du Toit C; Mohamed Z; McDonald A
Biol Blood Marrow Transplant; 2010 Oct; 16(10):1402-10. PubMed ID: 20385248
[TBL] [Abstract][Full Text] [Related]
66. Low transplant related mortality in older patients with hematologic malignancies undergoing autologous stem cell transplantation.
Villela L; Sureda A; Canals C; Sanz MA; Martino R; Valcárcel D; Altés A; Briones J; Gómez M; Brunet S; Sierra J
Haematologica; 2003 Mar; 88(3):300-5. PubMed ID: 12651269
[TBL] [Abstract][Full Text] [Related]
67. Outcomes Among High-Risk and Standard-Risk Multiple Myeloma Patients Treated With High-Dose Chemotherapy and Autologous Hematopoietic Stem-Cell Transplantation.
Kazmi SM; Nusrat M; Gunaydin H; Cornelison AM; Shah N; Kebriaei P; Nieto Y; Parmar S; Popat UR; Oran B; Shah JJ; Orlowski RZ; Champlin RE; Qazilbash MH; Bashir Q
Clin Lymphoma Myeloma Leuk; 2015 Nov; 15(11):687-93. PubMed ID: 26361647
[TBL] [Abstract][Full Text] [Related]
68. [Retrospective analysis on therapeutic effect of autologous hematopoietic stem cell transplantation in multiple myeloma patients].
Wang J; Fu CC; Wu DP; Sun AN; Xue SL; Xin X; Hu XH; Wang Y; Qiu HY; Jin ZM; Miao M; Tang XW; Han Y; Ma X; He GS; Chang WR; Chen SN
Zhonghua Yi Xue Za Zhi; 2013 Jan; 93(2):114-8. PubMed ID: 23648347
[TBL] [Abstract][Full Text] [Related]
69. Tandem autologous versus autologous/allogeneic transplantation for multiple myeloma: propensity score analysis.
Kawamura K; Ikeda T; Hagiwara S; Mori T; Shinagawa A; Nishiwaki K; Ohashi K; Kubonishi S; Fukuda T; Ito T; Tomita N; Ichinohe T; Kato K; Morishima Y; Atsuta Y; Sunami K; Kanda Y
Leuk Lymphoma; 2016 Sep; 57(9):2077-83. PubMed ID: 26961137
[TBL] [Abstract][Full Text] [Related]
70. Outcomes in patients with multiple myeloma with TP53 deletion after autologous hematopoietic stem cell transplant.
Gaballa S; Saliba RM; Srour S; Lu G; Brammer JE; Shah N; Bashir Q; Patel K; Bock F; Parmar S; Hosing C; Popat U; Delgado R; Rondon G; Shah JJ; Manasanch EE; Orlowski RZ; Champlin R; Qazilbash MH
Am J Hematol; 2016 Oct; 91(10):E442-7. PubMed ID: 27420405
[TBL] [Abstract][Full Text] [Related]
71. High-Dose Chemotherapy with Autologous Hematopoietic Stem Cell Transplantation in Relapsed or Refractory Primary CNS Lymphoma: A Retrospective Monocentric Analysis of Long-Term Outcome, Prognostic Factors, and Toxicity.
Seidel S; Nilius-Eliliwi V; Kowalski T; Vangala DB; Schlegel U; Schroers R
Cancers (Basel); 2022 Apr; 14(9):. PubMed ID: 35565230
[TBL] [Abstract][Full Text] [Related]
72. Abnormal body composition is a predictor of adverse outcomes after autologous haematopoietic cell transplantation.
Armenian SH; Iukuridze A; Teh JB; Mascarenhas K; Herrera A; McCune JS; Zain JM; Mostoufi-Moab S; McCormack S; Slavin TP; Scott JM; Jones LW; Sun CL; Forman SJ; Wong FL; Nakamura R
J Cachexia Sarcopenia Muscle; 2020 Aug; 11(4):962-972. PubMed ID: 32212263
[TBL] [Abstract][Full Text] [Related]
73. Sequential treatment with bortezomib plus dexamethasone followed by autologous hematopoietic stem cell transplantation in patients with multiple myeloma.
Zheng D; Li J; Huang BH; Liu JR; Zou WY; Su C
Chin Med J (Engl); 2012 Dec; 125(24):4454-9. PubMed ID: 23253719
[TBL] [Abstract][Full Text] [Related]
74. Are myeloma patients with renal failure candidates for autologous stem cell transplantation?
San Miguel JF; Lahuerta JJ; García-Sanz R; Alegre A; Bladé J; Martinez R; García-Laraña J; De La Rubia J; Sureda A; Vidal MJ; Escudero A; Pérez-Esquiza E; Conde E; García-Ruiz JC; Cabrera R; Caballero D; Moraleda JM; Leon A; Besalduch J; Hernandez MT; Rifon J; Hernandez F; Solano C; Palomera L; Parody R; Gonzalez JD; Mataix R; Maldonado J; Constela J; Carrera D; Bello JL; De Pablos JM; Pérez-Simón JA; Torres JP; Olanguren J; Prieto E; Acebede G; Peñarrubia MJ; Torres P; Díez-Martín JL; Rivas A; Sánchez JM; Díaz-Mediavilla J
Hematol J; 2000; 1(1):28-36. PubMed ID: 11920166
[TBL] [Abstract][Full Text] [Related]
75. Low CD34
Hyder MA; Goebel WS; Ervin KD; Schwartz JE; Robertson MJ; Thakrar TC; Albany C; Farag SS
Biol Blood Marrow Transplant; 2018 Jul; 24(7):1497-1504. PubMed ID: 29410296
[TBL] [Abstract][Full Text] [Related]
76. A Phase IIb, Multicenter, Open-Label, Safety, and Efficacy Study of High-Dose, Propylene Glycol-Free Melphalan Hydrochloride for Injection (EVOMELA) for Myeloablative Conditioning in Multiple Myeloma Patients Undergoing Autologous Transplantation.
Hari P; Aljitawi OS; Arce-Lara C; Nath R; Callander N; Bhat G; Allen LF; Stockerl-Goldstein K
Biol Blood Marrow Transplant; 2015 Dec; 21(12):2100-2105. PubMed ID: 26327631
[TBL] [Abstract][Full Text] [Related]
77. The influence of high-efficiency particulate air filtration on mortality among multiple myeloma patients receiving autologous stem cell transplantation.
Tsai CK; Yeh CM; Hong YC; Chen PM; Liu JH; Gau JP; Liu CJ
Sci Rep; 2021 Jun; 11(1):11789. PubMed ID: 34083620
[TBL] [Abstract][Full Text] [Related]
78. Comparison of fixed dose pegfilgrastim and daily filgrastim after autologous stem cell transplantation in patients with multiple myeloma autografted on a outpatient basis.
Ferrara F; Izzo T; Criscuolo C; Riccardi C; Viola A; Delia R; Carbone A; Celentano M
Hematol Oncol; 2011 Sep; 29(3):139-43. PubMed ID: 21922508
[TBL] [Abstract][Full Text] [Related]
79. Treatment of multiple myeloma.
San Miguel JF; Bladé Creixenti J; García-Sanz R
Haematologica; 1999 Jan; 84(1):36-58. PubMed ID: 10091392
[TBL] [Abstract][Full Text] [Related]
80. Outcomes with autologous stem cell transplant vs. non-transplant therapy in patients 70 years and older with multiple myeloma.
Lemieux C; Muffly LS; Rezvani A; Lowsky R; Iberri DJ; Craig JK; Frank MJ; Johnston LJ; Liedtke M; Negrin R; Weng WK; Meyer E; Shizuru J; Shiraz P; Arai S; Miklos DB; Sidana S
Bone Marrow Transplant; 2021 Feb; 56(2):368-375. PubMed ID: 32782351
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
